Bicycle Therapeutics Plc (BCYC)
3.89
+0.08
(+2.10%)
USD |
NASDAQ |
Oct 09, 16:00
3.89
0.00 (0.00%)
After-Hours: 20:00
Bicycle Therapeutics Cash from Operations (Quarterly) : -49.69M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -49.69M |
| March 31, 2026 | -65.81M |
| December 31, 2025 | -19.10M |
| September 30, 2025 | -70.63M |
| June 30, 2025 | -73.82M |
| March 31, 2025 | -86.70M |
| December 31, 2024 | -8.767M |
| September 30, 2024 | -40.49M |
| June 30, 2024 | -44.70M |
| March 31, 2024 | -70.83M |
| December 31, 2023 | -47.46M |
| September 30, 2023 | -1.006M |
| June 30, 2023 | 34.44M |
| March 31, 2023 | -46.83M |
| December 31, 2022 | -32.26M |
| September 30, 2022 | -4.952M |
| June 30, 2022 | -22.70M |
| Date | Value |
|---|---|
| March 31, 2022 | -26.14M |
| December 31, 2021 | -8.295M |
| September 30, 2021 | 21.90M |
| June 30, 2021 | -12.16M |
| March 31, 2021 | -16.23M |
| December 31, 2020 | -16.94M |
| September 30, 2020 | -9.807M |
| June 30, 2020 | -12.16M |
| March 31, 2020 | 20.98M |
| December 31, 2019 | -5.005M |
| September 30, 2019 | -11.23M |
| June 30, 2019 | -7.417M |
| March 31, 2019 | -5.078M |
| December 31, 2018 | -8.803M |
| September 30, 2018 | -4.683M |
| June 30, 2018 | -5.214M |
| March 31, 2018 | -7.322M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Autolus Therapeutics Plc | -25.16M |
| Akari Therapeutics Plc | -3.112M |
| Cellectis SA | -14.34M |
| DBV Technologies SA | -52.52M |
| Biodexa Pharmaceuticals Plc | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.266M |
| Cash from Financing (Quarterly) | -0.0501M |
| Free Cash Flow | -207.47M |
| Free Cash Flow Per Share (Quarterly) | -0.7157 |
| Free Cash Flow to Equity (Quarterly) | -49.23M |
| Free Cash Flow to Firm (Quarterly) | -49.92M |
| Free Cash Flow Yield | -76.70% |